An Open-label Phase I Dose-escalation Study to Evaluate the Safety, Tolerability, Maximum Tolerated Dose, Pharmacokinetics, and Pharmacodynamics of the Anti-C4.4a Antibody Drug Conjugate BAY1129980 in Subjects With Advanced Solid Tumors Known to Express C4.4a

Trial Profile

An Open-label Phase I Dose-escalation Study to Evaluate the Safety, Tolerability, Maximum Tolerated Dose, Pharmacokinetics, and Pharmacodynamics of the Anti-C4.4a Antibody Drug Conjugate BAY1129980 in Subjects With Advanced Solid Tumors Known to Express C4.4a

Recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Aug 2017

At a glance

  • Drugs Lupartumab amadotin (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Bayer
  • Most Recent Events

    • 13 Feb 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
    • 13 Feb 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
    • 12 May 2016 Planned End Date changed from 1 Apr 2017 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top